KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Change in Account Payables (2016 - 2025)

Pacific Biosciences Of California (PACB) has 16 years of Change in Account Payables data on record, last reported at $1.7 million in Q4 2025.

  • For Q4 2025, Change in Account Payables fell 52.55% year-over-year to $1.7 million; the TTM value through Dec 2025 reached $2.5 million, up 76.65%, while the annual FY2025 figure was $2.5 million, 76.65% up from the prior year.
  • Change in Account Payables reached $1.7 million in Q4 2025 per PACB's latest filing, up from $1.3 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $6.6 million in Q1 2024 and bottomed at -$5.6 million in Q3 2024.
  • Average Change in Account Payables over 5 years is $574050.0, with a median of $166500.0 recorded in 2021.
  • Peak YoY movement for Change in Account Payables: soared 4065.36% in 2022, then crashed 1520.0% in 2023.
  • A 5-year view of Change in Account Payables shows it stood at $6.2 million in 2021, then plummeted by 107.88% to -$486000.0 in 2022, then plummeted by 208.64% to -$1.5 million in 2023, then skyrocketed by 341.8% to $3.6 million in 2024, then crashed by 52.55% to $1.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Account Payables were $1.7 million in Q4 2025, $1.3 million in Q3 2025, and $1.0 million in Q2 2025.